User profiles for Sarah J. Wait
 | Sarah WaitUniversity of Washington Verified email at uw.edu Cited by 788 |
[HTML][HTML] New approaches to SCLC therapy: from the laboratory to the clinic
The outcomes of patients with SCLC have not yet been substantially impacted by the revolution
in precision oncology, primarily owing to a paucity of genetic alterations in actionable …
in precision oncology, primarily owing to a paucity of genetic alterations in actionable …
[PDF][PDF] MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate
Small cell lung cancer (SCLC) is a neuroendocrine tumor treated clinically as a single
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based on …
disease with poor outcomes. Distinct SCLC molecular subtypes have been defined based on …
[PDF][PDF] The lineage-defining transcription factors SOX2 and NKX2-1 determine lung cancer cell fate and shape the tumor immune microenvironment
The major types of non-small-cell lung cancer (NSCLC)—squamous cell carcinoma and
adenocarcinoma—have distinct immune microenvironments. We developed a genetic model of …
adenocarcinoma—have distinct immune microenvironments. We developed a genetic model of …
MYC-driven small-cell lung cancer is metabolically distinct and vulnerable to arginine depletion
Purpose: Small-cell lung cancer (SCLC) has been treated clinically as a homogeneous
disease, but recent discoveries suggest that SCLC is heterogeneous. Whether metabolic …
disease, but recent discoveries suggest that SCLC is heterogeneous. Whether metabolic …
ASCL1 represses a SOX9+ neural crest stem-like state in small cell lung cancer
…, CP Whitney, MR Guthrie, SJ Wait… - Genes & …, 2021 - genesdev.cshlp.org
ASCL1 is a neuroendocrine lineage-specific oncogenic driver of small cell lung cancer (SCLC),
highly expressed in a significant fraction of tumors. However,∼ 25% of human SCLC are …
highly expressed in a significant fraction of tumors. However,∼ 25% of human SCLC are …
Optogenetic microwell Array screening system: A high-throughput engineering platform for genetically encoded fluorescent indicators
Genetically encoded fluorescent indicators (GEFIs) are protein-based optogenetic tools that
change their fluorescence intensity when binding specific ligands in cells and tissues. GEFI …
change their fluorescence intensity when binding specific ligands in cells and tissues. GEFI …
Opto-MASS: a high-throughput engineering platform for genetically encoded fluorescent sensors enabling all-optical in vivo detection of monoamines and opioids
…, AK Matarasso, CA Zamorano, C Stine, SJ Wait… - BioRxiv, 2022 - biorxiv.org
Fluorescent sensor proteins are instrumental for detecting biological signals in vivo with
high temporal accuracy and cell-type specificity. However, engineering sensors with …
high temporal accuracy and cell-type specificity. However, engineering sensors with …
Machine learning-guided engineering of genetically encoded fluorescent calcium indicators
Here we used machine learning to engineer genetically encoded fluorescent indicators,
protein-based sensors critical for real-time monitoring of biological activity. We used machine …
protein-based sensors critical for real-time monitoring of biological activity. We used machine …
Inhibition of karyopherin β1-mediated nuclear import disrupts oncogenic lineage-defining transcription factor activity in small cell lung cancer
… J, Western blot showing undetectable levels of ASCL1 in SCLC-A subtype NCI-H2107
cells expressing dCas9-KRAB plus ASCL1.1 or ASCL1.2 gRNAs. K, Heatmap comparing …
cells expressing dCas9-KRAB plus ASCL1.1 or ASCL1.2 gRNAs. K, Heatmap comparing …
ASCL1 represses a latent osteogenic program in small cell lung Cancer in multiple cells of origin
ASCL1 is a neuroendocrine-lineage-specific oncogenic driver of small cell lung cancer (SCLC),
highly expressed in a significant fraction of tumors. However, ~25% of human SCLC are …
highly expressed in a significant fraction of tumors. However, ~25% of human SCLC are …